VistaGen Therapeutics's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2021 was $2.72 Mil.
VistaGen Therapeutics's quarterly Long-Term Capital Lease Obligation
declined
from Jun. 2021 ($3.25 Mil) to Sep. 2021 ($3.14 Mil) and
declined
from Sep. 2021 ($3.14 Mil) to Dec. 2021 ($2.72 Mil).
VistaGen Therapeutics's annual Long-Term Capital Lease Obligation
increased
from Mar. 2019 ($0.01 Mil) to Mar. 2020 ($3.72 Mil) but then
declined
from Mar. 2020 ($3.72 Mil) to Mar. 2021 ($3.35 Mil).
VistaGen Therapeutics Long-Term Capital Lease Obligation Historical Data
The historical data trend for VistaGen Therapeutics's Long-Term Capital Lease Obligation can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
VistaGen Therapeutics Annual Data
Trend
Mar12
Mar13
Mar14
Mar15
Mar16
Mar17
Mar18
Mar19
Mar20
Mar21
Long-Term Capital Lease Obligation
0.01
0.01
0.01
3.72
3.35
VistaGen Therapeutics Quarterly Data
Mar17
Jun17
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Long-Term Capital Lease Obligation
3.45
3.35
3.25
3.14
2.72
VistaGen Therapeutics (NAS:VTGN) Long-Term Capital Lease Obligation Explanation
Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.
Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:
1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.
VistaGen Therapeutics Long-Term Capital Lease Obligation Related Terms
Thank you for viewing the detailed overview of VistaGen Therapeutics's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.
VistaGen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of a major depressive disorder in patients with an inadequate response to standard antidepressants. The PH94B is a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia; PH10 is an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.04(3.92%) Volume: 1,926,517 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:VTGN has been successfully added to your 
